Year: 2025
Type: erratum
Abstract: In the article ‘Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study’ [Liver Cancer. 2023;12(3):262–276. https://doi.org/10.1159/000528034] by Xu et al., after publication, the authors found an error in Table 3, which represents the performance of the clinicopathologic-radiomic model on the validation cohort. The Area Under the Curve (AUC) with its 95% Confidence Interval (CI) was incorrectly listed in Table 3 as ‘0.876 (0.750–1.000)’, while the correct value should be listed as ‘0.884 (0.762–1.000).’The corrected Table 3 is shown here.
Source: Liver Cancer
DOI: 10.1159/000543481
Language: Dutch
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,590
OpenAlex ID: W4407302636